Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
Yan D, Liu C, Li X, Moore M, Xu R, Sanborn RE, Gadgeel SM, Millward M, Shi Z, Wang Y, Stazzone K, Chisamore MJ, Zhang L
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.